CompletedPhase 4

Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus

Egypt36 participantsStarted 2023-05-01

Plain-language summary

Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan. It is classified as a nutraceutical and it is used mainly orally for the therapy of osteoarthritis since GlcN has immunoregulatory capacity and anti-inflammatory effects. Given the Oral lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising therapeutic option. The investigators compared the clinical efficacy of topical glucosamine to topical corticosteroid in the treatment of symptomatic OLP and investigated the effect of these two treatment modalities on the expression of tumor necrosis factor-alpha (TNF-α) in oral lichen planus lesions

Who can participate

Age range25 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinically proven painful bullous/erosive or atrophic forms of OLP * Histopathologically proven bullous/erosive or atrophic forms of OLP Exclusion Criteria: * Lichenoid lesions. * Presence of systemic conditions * Smoking. * Hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in medical history. * Pregnancy or breast-feeding. * Presence of skin lesions. * History of previous treatments potentially effective on OLP. * Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus. * Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites. * Refusing to participate in the study. * Vulnerable groups

What they're measuring

Clinical score (CS)

Timeframe: Change from Baseline at 12 weeks

Trial details

NCT IDNCT07114016

SponsorFuture University in Egypt

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-15